Ruxolitinib as a therapy choice for refractory pruritus in a patient with essential thrombocythemia with CALR mutation-Reference-Cited by-同舟云学术

Ruxolitinib as a therapy choice for refractory pruritus in a patient with essential thrombocythemia with CALR mutation

Published:2023-01-25 Issue:1 Volume:10 Page:001-002
ISSN:2455-5282
Container-title:Global Journal of Medical and Clinical Case Reports
language:
Short-container-title:Glob J Medical Clin Case Rep

Author:

Kubra Cerci,Pusem Patir

Abstract

Refractory pruritus associated with Essential Thrombocythemia (ET) is rare. Herein, we present the first report of resistant pruritus responsive to ruxolitinib in an ET patient with a calreticulin mutation.

Publisher

Peertechz Publications Private Limited

Subject

General Medicine

Reference6 articles.

1. 1. Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012 Nov 20;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863. Epub 2012 Oct 15. Erratum in: J Clin Oncol. 2012 Dec 20;30(36):4590. Ferarri, Maria L [corrected to Ferrari, Maria L]. PMID: 23071245; PMCID: PMC4872304.

2. 2. Gugliotta L, Papayannidis C, Piccin A. Hydroxyurea treatment in 1075 patients with essential thrombocythemia and occurrence of extra-hematological adverse events: a preliminary report of the Registro Italiano Trombocitemia (RIT). Blood (ASH Annual Meeting Abstracts) 2010; 116: 1973. https://doi.org/10.1182/blood.V116.21.1973.1973

3. 3. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16;363(12):1117-27. doi: 10.1056/NEJMoa1002028. PMID: 20843246; PMCID: PMC5187954.

4. 4. Ishii T, Wang J, Zhang W, Mascarenhas J, Hoffman R, Dai Y, Wisch N, Xu M. Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood. 2009 Jun 4;113(23):5942-50. doi: 10.1182/blood-2008-09-179416. Epub 2009 Feb 4. PMID: 19196660.

5. 5. Weisshaar E, Apfelbacher C, Jäger G, Zimmermann E, Bruckner T, Diepgen TL, Gollnick H. Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. Br J Dermatol. 2006 Nov;155(5):957-64. doi: 10.1111/j.1365-2133.2006.07430.x. PMID: 17034525.